Remove 2010 Remove FDA Remove Prescription
article thumbnail

You can’t afford to get cancer

World of DTC Marketing

Among adults 65 and older with Medicare coverage, average annual out-of-pocket costs for medical services and prescription drugs were highest in the initial phase of care (first 12 months after diagnosis) — $2,200 and $243, respectively — and the end-of-life phase (12 months before death) — $3,823 and $448, respectively. ScienceNews.com.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. Currently, Jazz Pharmaceuticals’s nabiximols is the only cannabinoid approved for pain, receiving approval in Israel, in August 2010.

Medical 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?

Marketing 103
article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Pharmaceutical companies – and the FDA – are embracing FDCs. From 1990 through 2013, the FDA approved 131 FDC products, on average 5.7 Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. Of those 131 approved FDCs, 98 were oral dosage forms.

article thumbnail

THEPM360TRAILBLAZER AWARD WINNER – Lifetime Achievement Award – Adam Schechter, CEO and Chairman, Labcorp

PM360

He was Executive VP and President of Merck’s Global Human Health Division from 2010 to 2019. Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. Food and Drug Administration (FDA) approval. It was the first PD-1 inhibitor to receive U.S.

Ethics 59
article thumbnail

The Witty Answer to GSK’s Future

Pharmaceutical Technology

Important elements within this expectation are the build up of strong contributions from Rotarix, Cervarix and Tykerb, while the outlook for GSK’s important asthma franchise becomes less clear beyond 2010. PT: Glaxo shares have fallen 17% in the past year. .